Lineage Cell Therapeutics (LCTX) Operating Expenses (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Operating Expenses of $9.3 million for Q1 2026, up 16.37% year-over-year from $8.0 million in Q1 2025, and down 29.17% quarter-over-quarter from $13.2 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Operating Expenses (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $9.3 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 16.37% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $52.5 million (up 69.97% YoY), while the FY2025 annual figure was $51.2 million, up 65.2% from the prior year.
- Operating Expenses for Q1 2026 stood at $9.3 million, down from $13.2 million in the prior quarter.
- The five-year high for Operating Expenses was $22.5 million in Q2 2025, with the low at $7.3 million in Q2 2024.
- The 5-year median for Operating Expenses is $8.2 million (2023), against an average of $9.5 million.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses tumbled 71.06% in 2022, then jumped 209.9% in 2025.
- Lineage Cell Therapeutics' Operating Expenses stood at $8.5 million in 2022, then dropped by 3.05% to $8.2 million in 2023, then retreated by 2.64% to $8.0 million in 2024, then soared by 64.9% to $13.2 million in 2025, then declined by 29.17% to $9.3 million in 2026.
- Business Quant data shows LCTX's Operating Expenses at $9.3 million in Q1 2026, $13.2 million in Q4 2025, and $7.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 9.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.99 Mn |
| Mar 31, 2026 | 9.32 Mn |
| Dec 31, 2025 | 13.16 Mn |
| Sep 30, 2025 | 7.47 Mn |
| Jun 30, 2025 | 22.55 Mn |
| Mar 31, 2025 | 8.01 Mn |
| Dec 31, 2024 | 7.98 Mn |
| Sep 30, 2024 | 7.62 Mn |
| Jun 30, 2024 | 7.28 Mn |
| Mar 31, 2024 | 8.11 Mn |
| Dec 31, 2023 | 8.19 Mn |
| Sep 30, 2023 | 7.95 Mn |
| Jun 30, 2023 | 8.25 Mn |
| Mar 31, 2023 | 9.03 Mn |
| Dec 31, 2022 | 8.45 Mn |
| Sep 30, 2022 | 8.01 Mn |
| Jun 30, 2022 | 8.57 Mn |
| Mar 31, 2022 | 11.46 Mn |
| Dec 31, 2021 | 29.20 Mn |
| Sep 30, 2021 | 8.13 Mn |